Biodimension raises Rs 8 crore angel round led by IAN Angel Fund
What's the deal? Bengaluru-based life sciences startup Biodimension TechnologyDealroom has a profile for this one. Try Dealroom → has raised $80 million in an angel round led by IAN Angel Fund. Campus Angels NetworkDealroom has a profile for this one. Try Dealroom →, Dr. Sampath Srisailam, and angel investor Aaryan Baid also participated.
Founded by Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension develops biofabricated human tissue and organoid models as alternatives to animal testing for pharmaceutical, biotech, and cosmetic companies.
The funds will go toward product development, laboratory expansion, team growth, and commercialisation in India and overseas.
Why now? Regulatory pressure to reduce animal testing is mounting globally, creating demand for human-relevant testing models. Biodimension's portfolio — which includes tissue models, a pan-cancer tumour microenvironment biobank, and a Bioassay-as-a-Service (BaaS) platform — positions it to capture that shift.
The startup has already established collaborations with pharma firms, research institutions, and contract research organisations across India and Singapore. It plans to expand into additional Southeast Asian markets next.
What could go wrong? Replacing entrenched animal-testing workflows is a slow, regulation-heavy process. Biodimension will need to prove its models meet the validation standards that pharma and biotech companies require before they switch.
Scaling laboratory infrastructure is also capital-intensive, and the startup will face competition from well-funded global players in the organoid and organ-on-a-chip space.
The signal: Biodimension is still at the early stage, yet it has already secured backing from both IAN Angel Fund and returning investor Campus Angels Network — a sign that conviction is building around animal-testing alternatives even at the pre-commercial phase in India. With global regulators increasingly mandating non-animal testing methods and the startup already active in Singapore, the round suggests angel investors are willing to bet early on platforms whose regulatory tailwinds extend well beyond their home market.
Read more: m.dailyhunt.in
